Editorial Board ::: Drug Metabolism Letters

ISSN: 1874-0758 (Online)
ISSN: 1872-3128 (Print)


Volume 11, 4 Issues, 2017


Download PDF Flyer




Drug Metabolism Letters

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Zhiyang Zhao
Alliance Pharma
Malvern, PA
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Zhiyang Zhao (Biography
Zhiyang Zhao

Zhiyang Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Tech, Blacksburg, Virginia, USA. Dr. Zhao’s biopharmaceutical/pharmaceutical work experience encompasses over 25 years of research in metabolic and pharmacokinetic properties of compounds for drug discovery and development at Pfizer, GlaxoSmithKline and Amgen. Currently, Dr. Zhao serve as Chief Scientific Officer (CSO) at Alliance Pharma, Inc. and appointed as an adjunct professor at the School of Pharmacy, the University of North Carolina at Chapel Hill. Dr. Zhao has published over 50 peer reviewed original research papers and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.

)

Alliance Pharma
Malvern, PA
USA



Co-Editor:

Suresh K Balani
Takeda Pharmaceuticals International Company
Cambridge, MA
USA


Associate Editors:

Region: USA
Michael Sinz
Bristol Myers Squibb
Wallingford, CT
USA

Shufeng Zhou
University of South Florida
Florida, FL
USA

Region: Asia
Ken-ichi Fujita (Biography
Ken-ichi Fujita

Dr. Fujita obtained a Ph.D. from the Graduate School of Pharmaceutical Sciences, Hokkaido University (Sapporo, Japan). Dr. Fujita also holds a Bachelor of Engineering from the School of Engineering, Tohoku University (Sendai, Japan). Currently Dr. Fujita is a Professor in the Institute of Molecular Oncology, Showa University. His present research field is clinical pharmacology in cancer pharmacotherapy. He has published more than 100 scientific publications. Dr. Fujita is currently the Associate Editor of this journal (Current Drug Metabolism).

)

Showa University
Tokyo
Japan

Lee Jia
Fuzhou University
Fujian
China

Region: Europe
Nico P.E. Vermeulen
Vrije Universiteit Amsterdam
Amsterdam
The Netherlands


Editorial Board Members:

G.D. Bowers
GlaxoSmithKline
Research Triangle Park, NC
USA

J.S. Daniels
Vanderbilt University Medical Center
Nashville, TN
USA

W.G. Humphreys
Bristol-Myers Squibb
Princeton, NJ
USA

R.S. King (Biography
R.S. King

Dr. King earned a doctorate (Ph.D.) in Medicinal Chemistry from the University of Iowa, Iowa City. Her postdoctoral fellowship was in molecular toxicology at the National Center for Toxicological Research, followed immediately by earning a faculty position at the University of Rhode Island, College of Pharmacy in 1999. Dr. King is currently Professor of Biomedical and Pharmaceutical Sciences. Dr. King's research spans protein structural biology, receptor-based drug design, all aspects of drug-xenobiotic-hormone metabolism, and liver enzymology.

)

University of Rhode Island
Kingston, RI
USA

A.P. Li (Biography
A.P. Li

Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.

)

In Vitro ADMET Laboratories
Columbia, MD
United States

M. Moghaddam (Biography
M. Moghaddam

Dr. Mehran F. Moghaddam obtained his PhD in medicinal chemistry at Oregon State University-School of Pharmacy and investigated novel lipid metabolism at University of California-Davis as a postdoctoral researcher. He also completed an executive MBA at University of Southern California. He started his industrial career by joining DuPont in 1995. Subsequently, he worked in Pfizer and Celgene. He is currently the head of Discovery Drug Metabolism and Pharmacokinetics (DMPK) at Celgene, a global biopharmaceutical company with marketed blockbuster drugs in oncology and anti-inflammatory spaces.

Dr. Moghaddam has been a co-inventor on more than 5 patents. He has authored/co-authored more than 50 manuscripts on a variety of subject matters. He is on the editorial board of Drug Metabolism Letters and DARU. Additionally, he is a section editor for Current Medicinal Chemistry.

)

Celgene Corporation
San Diego, CA
USA

C. Prakash
CP Pharma Consulting Principal, Drug Metabolism and Pharmacokinetics
MA
USA

J.F. Rusling
University of Connecticut
Storrs, CT
USA

R.J. Weaver (Biography
R.J. Weaver

Dr. Weaver obtained his first degree in Biochemistry & Toxicology (Hons) from the University of Surrey, Guildford, and PhD from the Dept. of Medicine & Therapeutics, University of Aberdeen. Dr. Weaver also holds a Masters of Business Administration (MBA) from the Warwick Business School, Warwick University, UK. Currently Dr Weaver is Associate Scientific Director, Servier Group, France. Affiliations included Fellow of the Royal Society of Chemistry, European Registered Toxicologist and Committee Member of the Preclinical Drug Safety and Biological Discovery Expert Committees.

)

Institut de Recherches Internationales Servier
Suresnes Cedex
France

A.M. Yu (Biography
A.M. Yu

Dr. Aiming Yu is a Professor in the Department of Biochemistry & Molecular Medicine and a member of the Comprehensive Cancer Center at UC Davis School of Medicine. He also directs the PK/PD Bioanalytical Core Facility in support of drug development programs at UC Davis. Prof. Yu’s research interests include microRNA pharmacoepigenetics, and cancer pharmacology and therapy. His current research focuses on the delineation of mechanistic functions of noncoding RNAs in the control of cellular processes including drug disposition and tumor progression, and development of novel noncoding RNA-based therapeutics.

)

University of California-Davis
Sacramento, CA
USA

D. Capone
Federico II University
Naples
Italy

R. Dickinson
University of Queensland at Royal Brisbane Hosp.
Queensland
Australia

M. Kajbaf
GlaxoSmithKline S.p.A.
Fleming, Verona
Italy

G.N. Kumar (Biography
G.N. Kumar

Gondi N. Kumar obtained B. Pharm from Kakatiya University, India, M. Pharm from Andhra University, India, Ph.D. from University of Florida, Gainesville, FL, and post-doctoral fellowship evaluating metabolism of paclitaxel at the Medical University of South Carolina. He is a diplomate of American Board of Toxicology. Prior to Celgene, he had productive careers at Abbott and Amgen, as principal DMPK investigator for lopinavir/ritonavir (KaletraTM), cinacalcet (SensiparTM) and abarelix (PlenaxisTM). He has published over 50 research papers, PhRMA perspectives and book chapters, and is a co-inventor on multiple patents.

)

Celgene Corporation
Summit, NJ
USA

B.L. Lum
Genentech Research and Early Development
South San Francisco, CA
USA

A.F. Nassar
Brandies University
Waltham, MA
USA

S. Pusalkar (Biography
S. Pusalkar

Dr. Pusalkar obtained a doctorate degree (Ph.D.) in Medicinal Chemistry from Massachusetts College of Pharmacy and Health Sciences, Boston, MA. Dr. Pusalkar has more than 15 years of experience in drug metabolism and pharmacokinetics field and currently leads the Enzymology Group at Takeda Pharmaceuticals, Intl’ Co. in Cambridge, MA.

)

Takeda Pharmaceuticals Inc.
Cambridge, MA
USA

M. Soars
Bristol-Myers Squibb
Wallingford, CT
USA

W. Xie
University of Pittsburgh School of Pharmacy
Pittsburgh, PA
USA

A. Collier (Biography
A. Collier

Dr. Collier's sub-specialty is drug metabolism and pharmacokinetics, primarily the phase II (conjugation) enzymes, with a strong focus on pregnancy and pediatrics. A winner of the 2011 SimCYP Consortium Award for Most Informative Report ("in recognition of scientific research that is leading the field in ADME, IVIVE, pharmacokinetics, modeling and simulation"), Dr. Collier uses a combination of wet laboratory work and in silico modeling to provide greater understanding of developmental pharmacology and improve drug/chemical safety. Along with her collaborators, she also performs research and publishes regularly in the fields of human and environmental toxicology and endocrinology.

)

University of British Columbia
Vancouver
Canada

H. Glatt
German Institute of Human Nutrition (DIfE)
Nuthetal
Germany

E. Kantharaj
R & D Technical, D3, A*STAR
Singapore

T. Kàroly
Preclinical Imaging Center
Budapest
Hungary

S. Mandlekar (Biography
S. Mandlekar

Sandhya Mandlekar is the Director of Pharmaceutical Candidate Optimization Department at the Biocon Bristol-Myers Squibb R&D Center (BBRC) in Bangalore, India. She also worked in the non-clinical DMPK field at BMS, NJ and DuPont Pharmaceuticals, DE for several years. She received her Ph.D. degree in Pharmaceutical Sciences from the College of Pharmacy at the University of Illinois, Chicago. Sandhya was responsible for setting up and equipping the laboratories, recruitment and staffing, and directing a group of scientists in drug metabolism, pharmacokinetics, bioanalytical sciences, and toxicology at the BBRC. She has published over 50 peer-reviewed articles and also serves as a reviewer for reputed journals.

)

Bristol-Myers Squibb India Pvt. Ltd.
Bangalore
India

K.B. Park
University of Liverpool
Liverpool
UK

M.S. Roberts
University of South Australia
Adelaide
Australia

M. Ulgen
Acibadem University
Istanbul
Turkey

H. Yamazaki (Biography
H. Yamazaki

Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).

)

Showa Pharma University
Tokyo
Japan



Reviewer Panel:

1. M. Gooyit (USA)
4. M. Liu (USA)
7. D. Brian (USA)
10. M. Chetty (Australia)
13. M.T. Donato (Spain)
16. D. Fuchs (Austria)
19. K. Grime (UK)
22. N. Helsby (New Zealand)
25. M. Hu (USA)
28. H. Jeong (USA)
31. R.A. Kemper (USA)
34. J. Lambert (USA)
37. F. Martel (Portugal)
40. R.P. Meyer (Germany)
43. A. Palotas (Hungary)
46. W. Tang (USA)
49. M. Vastag (Hungary)
52. Z. Yan (USA)
2. L. Berry (USA)
5. Y. Guo (USA)
8. E. Chan (Singapore)
11. B. Chowbay (Singapore)
14. Z. Dvorak (Czech Republic)
17. A. Galetin (UK)
20. J. Gu (China)
23. N. Hewitt (Germany)
26. B. Houston (UK)
29. Y. Jounaidi (USA)
32. G.M. Kirby (Canada)
35. M.-C. Liu (USA)
38. H.H. Maurer (Germany)
41. B. Moorthy (USA)
44. E. Schuetz (USA)
47. R. Tolando (Germany)
50. K. Venkatakrishnan (USA)
53. C.-H. Yun (Republic of Korea)
3. C. Guo (USA)
6. P. Anzenbacher (Czech Republic)
9. K.-C. Cheng (USA)
12. C. Collins (USA)
15. A. El-Kadi (Canada)
18. L.L. Gan (USA)
21. J. Hakkola (Finland)
24. P. Honkakoski (Finland)
27. F. Innocenti (USA)
30. A.S. Kalgutkar (USA)
33. M. Kranendonk (Portugal)
36. P.H. Marathe (USA)
39. A. McLachlan (Australia)
42. A. Nishikawa (Japan)
45. M.-R. Shiran (Iran)
48. Y.-F. Ueng (Taiwan)
51. E.L. Woodahl (USA)
54. J.Y. Zhang (China)
Advertisement
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals




Related eBooks



Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science